Literature DB >> 1772686

Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea.

S Nigam1, C Benedetto, M Zonca, I Leo-Rossberg, H Lübbert, J Hammerstein.   

Abstract

Prostanoids, leukotrienes and platelet-activating factor were measured by radioimmunoassay in menstrual blood of seven women with primary dysmenorrhea and five healthy controls. The eicosanoids and PAF concentrations in dysmenorrheic patients were significantly higher than those found in healthy women (P less than 0.005 for PGF2 alpha, 11-dehydro-TXB2, 2,3-dinor-TXB2 and LTC4/D4; P less than 0.001 for PAE; P less than 0.05 for PGE2 and 2,3-dinor-6-keto-PGF1 alpha). Whereas no relationship could be found between the concentrations of PGF2 alpha, PGE2, 11-dehydro- and 2,3-dinor-TXB2 and severity of primary dysmenorrhea, a close correlation between LTC4/D4 and PAF and severity of the disease was observed, particularly in patients who responded poorly to therapy with prostaglandin synthetase inhibitors. We conclude that the hyperstimulation of myometrial activity is not caused by selective stimulation of one metabolic pathway of arachidonic acid, but rather by an overall stimulation of phospholipid metabolism. The assessment of prostanoids, leukotrienes and PAF in menstrual blood many be useful as a direct index of primary dysmenorrhea, and the development of their antagonists may have therapeutic implications in improved treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772686

Source DB:  PubMed          Journal:  Eicosanoids        ISSN: 0934-9820


  8 in total

1.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

Review 2.  A contemporary approach to dysmenorrhea in adolescents.

Authors:  Zeev Harel
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  A narrative review of medical, chiropractic, and alternative health practices in the treatment of primary dysmenorrhea.

Authors:  Lolita G Spears
Journal:  J Chiropr Med       Date:  2005

Review 4.  Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment.

Authors:  Folabomi A Oladosu; Frank F Tu; Kevin M Hellman
Journal:  Am J Obstet Gynecol       Date:  2017-09-06       Impact factor: 8.661

5.  Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium.

Authors:  Ana Babic; Holly R Harris; Allison F Vitonis; Linda J Titus; Susan J Jordan; Penelope M Webb; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Kristine Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Susanne K Kjaer; Joellen Schildkraut; Andrew Berchuck; Celeste L Pearce; Anna H Wu; Daniel W Cramer; Kathryn L Terry
Journal:  Int J Cancer       Date:  2017-09-21       Impact factor: 7.396

Review 6.  Acupuncture for Primary Dysmenorrhea: A Potential Mechanism from an Anti-Inflammatory Perspective.

Authors:  Wen-Yan Yu; Liang-Xiao Ma; Zhou Zhang; Jie-Dan Mu; Tian-Yi Sun; Yuan Tian; Xu Qian; Yi-Dan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-03       Impact factor: 2.629

7.  Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data.

Authors:  Jayne E Edwards; R Andrew Moore; Henry J McQuay
Journal:  BMC Womens Health       Date:  2004-07-20       Impact factor: 2.809

8.  Association of endocannabinoids with pain in endometriosis.

Authors:  Thomas Andrieu; Andrea Chicca; Daniele Pellegata; Nick A Bersinger; Sara Imboden; Konstantinos Nirgianakis; Juerg Gertsch; Michael D Mueller
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.